Schwieterman William D 4
4 · MATEON THERAPEUTICS INC · Filed Apr 16, 2018
Insider Transaction Report
Form 4
Schwieterman William D
Director
Transactions
- Purchase
Common Stock B Warrant (Right to Buy)
2018-04-12+312,500→ 312,500 totalExercise: $0.40→ Common Stock (312,500 underlying) - Purchase
Common Stock
2018-04-12+625,000→ 625,747 total - Purchase
Common Stock A Warrant (Right to Buy)
2018-04-12+312,500→ 312,500 totalExercise: $0.40From: 2018-04-12Exp: 2020-04-12→ Common Stock (312,500 underlying)
Footnotes (3)
- [F1]The reported securities are included within 2.5 Units purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share.
- [F2]The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date").
- [F3]The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years.